GLP-1 medications and PCOS weight loss: what the before-and-afters leave out

What did @catreaamcknight actually say?

Honestly? Not much, medically speaking. The transcript is entirely song lyrics: "walking with patience," "keeping the faith," "receiving his grace." There are no dosing claims, no before-and-after testimonials spoken aloud, no assertions about GLP-1 medications curing or treating PCOS. The video's medical content lives entirely in its hashtags and visual framing, not the words.

That context matters. The hashtags #pcos, #beforeandafter, and #transformation, combined with the GLP-1 category tag, strongly imply this is a weight loss or PCOS management journey video. Viewers will reasonably read it that way. But the creator never actually says anything factually verifiable about treatment, dosing, or outcomes. We're fact-checking a frame more than a statement.

Does the science back this up?

There's real science behind GLP-1 use in PCOS, though it's still emerging. The video doesn't cite any of it, but we can fill that gap.

PCOS affects roughly 8-13% of reproductive-age women globally and is strongly associated with insulin resistance, which is where GLP-1 receptor agonists enter the conversation. A 2023 randomized controlled trial by Elkind-Hirsch et al. published in Fertility and Sterility found that liraglutide improved menstrual regularity, androgen levels, and body weight in women with PCOS compared to placebo. Semaglutide data is less mature for PCOS specifically, but mechanistically, the insulin-sensitizing and weight-reducing effects are plausible pathways to symptom improvement.

A 2022 meta-analysis by Tay et al. in Obesity Reviews found GLP-1 agonists produced significantly greater weight loss than placebo in women with PCOS, with some improvement in hormonal markers. These are encouraging findings, but not a cure. Menstrual cycles don't always normalize, fertility isn't guaranteed to improve, and long-term data in this specific population remains limited.

What did they get wrong (or right)?

The creator didn't get anything factually wrong, because they didn't make any factual claims. That's worth saying plainly. Singing about faith and patience over a transformation montage is not medical misinformation. It's a personal narrative.

What the video does, without saying it, is imply a clean before-and-after story. That framing can be quietly misleading for people with PCOS who are earlier in their journey. GLP-1 medication results are not linear, and PCOS adds complexity. Weight loss with these medications is real but variable. A 2021 trial by Wadden et al. in the New England Journal of Medicine showed roughly 15% body weight reduction with semaglutide 2.4mg, but standard deviation was wide. Some people lose significantly less.

The creator deserves credit for not overclaiming. They're sharing an emotional moment, not a protocol. That's a meaningful distinction in a space full of people selling courses about their "PCOS cure."

What should you actually know?

If you have PCOS and you're watching transformation content about GLP-1 medications, here's what the research actually supports and where it stops.

• GLP-1 receptor agonists are not FDA-approved specifically for PCOS. Their use in that context is off-label, which is legal and common, but means the evidence base is thinner than for type 2 diabetes or general obesity indications.
• Weight loss from GLP-1 medications can improve PCOS symptoms like irregular periods, elevated androgens, and insulin resistance, but symptom improvement is not guaranteed and varies person to person.
• Stopping GLP-1 medications is associated with weight regain. A 2022 withdrawal study by Wilding et al. in Diabetes, Obesity and Metabolism found participants regained roughly two-thirds of lost weight within a year of stopping semaglutide.
• Anyone considering these medications for PCOS should have a real conversation with an endocrinologist or reproductive endocrinologist, not just a primary care telehealth visit. The hormonal picture in PCOS is complicated enough to warrant specialist input.
• Transformation content, even well-meaning content, rarely shows the full picture: the side effects, the plateau months, the cost, the monitoring requirements, or what happens if the medication is discontinued.